CORAT THERAPEUTICS

CORAT Therapeutics GmbH develops innovative therapeutic drugs composed of novel fully human neutralizing antibodies against COVID-19. CORAT antibodies very efficiently neutralize SARS-CoV-2 and stop its spread within the human body. Our lead product, COR-101, decreased the virus load in the lung by more than 99 % in the hamster COVID-19 model, and induced recovery after 2 days, compared to 7 days untreated.

Also known as: CORAT Therapeutics GmbH

Registration numbers: HRB 208500 (W)

Primary location: Braunschweig Germany